1,4-alpha-glucan-branching enzyme (GBE1)

1,4-alpha-glucan-branching enzyme (GBE1) is a critical enzyme in the glycogen biosynthetic pathway, responsible for introducing alpha-1,6-glycosidic branches into the growing glycogen polymer [UniProt: P35573]. By transferring a segment of alpha-1,4-linked glucose units to the C-6 position of a glucose residue, it ensures the formation of a highly branched, soluble glycogen structure that allows for rapid glucose mobilization [NCBI Gene: 2632]. A deficiency in GBE1 activity leads to the accumulation of abnormal, poorly branched glycogen known as polyglucosan, which is the hallmark of Glycogen Storage Disease Type IV (Andersen disease) and Adult Polyglucosan Body Disease (APBD) [OMIM: 607831]. These conditions result in severe tissue damage, ranging from infantile liver cirrhosis and cardiomyopathy to late-onset progressive neurodegeneration [StatPearls: Glycogen Storage Disease Type IV]. Currently, GBE1 is a primary focus for therapeutic development through gene therapy, enzyme replacement, and the identification of pharmacological chaperones to stabilize the enzyme or reduce toxic polyglucosan levels [PubMed: 28864356]. While no direct small molecule inhibitors are in clinical use, the enzyme's role in glucose homeostasis makes it a significant target for treating rare metabolic and neurological disorders.

Other names

Glycogen branching enzymeAmylo-(1,4->1,6)-transglycosylaseQ-enzymeAlpha-1,4-glucan-6-alpha-glucosyltransferaseGBE1,4-alpha-glucan branching enzyme

Gene replacement therapy to restore enzymatic activity, substrate reduction therapy to minimize polyglucosan accumulation, and pharmacological chaperoning to stabilize misfolded proteins.